Although comparison between the results of this study with actual administration of EGFR-TKIs and the results of those other studies is difficult, it is unclear whether osimertinib should be recommended as first-line treatment for patients aged ≥75 years with EGFR mutation-positive, nonsmall cell lung cancer. This evidence concerns the gene EGFR and lung cancer.